Lyka Labs zooms on getting product permission from CDSCO for Tofacitinib Ointment
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lyka Labs is currently trading at Rs. 123.00, up by 4.70 points or 3.97% from its previous closing of Rs. 118.30 on the BSE.
The scrip opened at Rs. 116.25 and has touched a high and low of Rs. 125.75 and Rs. 116.25 respectively. So far 14701 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 155.65 on 19-Jan-2023 and a 52 week low of Rs. 89.00 on 25-May-2023.
Last one week high and low of the scrip stood at Rs. 127.90 and Rs. 115.90 respectively. The current market cap of the company is Rs. 410.32 crore.
The promoters holding in the company stood at 54.58%, while Institutions and Non-Institutions held 0.58% and 44.85% respectively.
Lyka Labs has received the product permission from the Central Drugs Standard Control Organization of India (CDSCO) to Manufacture and Market Tofacitinib Ointment 2% w/w. The company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.
Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.
